• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    1/3/24 4:31:05 PM ET
    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • Portage Biotech (NASDAQ:PRTG) shares moved upwards by 20.6% to $1.7 during Wednesday's after-market session. The company's market cap stands at $33.6 million.
    • BIMI Intl Medical (NASDAQ:BIMI) stock rose 9.62% to $2.05. The market value of their outstanding shares is at $23.7 million.
    • Molecular Partners (NASDAQ:MOLN) shares increased by 9.6% to $5.48. The company's market cap stands at $180.0 million.
    • Nemaura Medical (NASDAQ:NMRD) shares rose 9.28% to $0.14. The market value of their outstanding shares is at $4.0 million.
    • Bright Green (NASDAQ:BGXX) stock rose 8.62% to $0.3. The company's market cap stands at $55.5 million.
    • Celularity (NASDAQ:CELU) shares rose 6.04% to $0.3. The market value of their outstanding shares is at $56.9 million.

    Losers

    • Biora Therapeutics (NASDAQ:BIOR) shares declined by 11.5% to $1.16 during Wednesday's after-market session. The company's market cap stands at $31.5 million.
    • ABVC BioPharma (NASDAQ:ABVC) shares declined by 8.3% to $1.77. The company's market cap stands at $13.7 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares declined by 7.86% to $1.29. The market value of their outstanding shares is at $10.9 million.
    • Akanda (NASDAQ:AKAN) shares fell 6.44% to $0.47. The market value of their outstanding shares is at $1.8 million.
    • Ocean Biomedical (NASDAQ:OCEA) shares fell 6.11% to $0.64. The market value of their outstanding shares is at $21.8 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares decreased by 5.67% to $0.5. The market value of their outstanding shares is at $7.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $AKAN
    $BGXX
    $BIMI

    CompanyDatePrice TargetRatingAnalyst
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Celularity Inc.
    $CELU
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    Celularity Inc.
    $CELU
    12/22/2022Outperform → Perform
    Oppenheimer
    Molecular Partners AG
    $MOLN
    8/30/2022Outperform → Sector Perform
    RBC Capital Mkts
    Molecular Partners AG
    $MOLN
    8/29/2022$30.00 → $8.00Outperform → Mkt Perform
    SVB Leerink
    Portage Biotech Inc.
    $PRTG
    7/18/2022$26.00Outperform
    Oppenheimer
    Celularity Inc.
    $CELU
    6/22/2022$15.00Buy
    H.C. Wainwright
    Molecular Partners AG
    $MOLN
    5/25/2022Underperform → Neutral
    Credit Suisse
    More analyst ratings

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    SEC Filings

    View All

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    4/2/26 5:25:02 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form NT 10-K filed by Celularity Inc.

    NT 10-K - Celularity Inc (0001752828) (Filer)

    3/31/26 5:13:34 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ENDRA Life Sciences Inc.

    10-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    3/31/26 5:10:48 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Molecular Partners AG with a new price target

    H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00

    1/27/26 8:47:34 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Celularity downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

    1/30/23 7:11:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity downgraded by Oppenheimer

    Oppenheimer downgraded Celularity from Outperform to Perform

    12/22/22 7:40:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

    4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    9/5/24 3:28:10 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    8/29/24 4:30:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. The Company intends to continue executing on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.

    3/31/26 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition

    Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its wholly owned subsidiary, First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, are pleased to announce an expansion of its dark fiber network with the addition of approximately 200 kilometres, increasing total network coverage to approximately 900 kilometres across Central Mexico.This milestone is expected to materially advance FTF's strategy to build a scaled, high-margin, cash-flow-generating digital infrastructure platform in what the Company believes is one of Latin America's most attractive and undersupplied connectivity ma

    3/26/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

    Board to evaluate a range of alternatives while continuing to support core business priorities ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company. E

    3/25/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    1/23/26 7:44:04 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

    Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug dev

    8/21/25 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Financials

    Live finance-specific insights

    View All

    Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

    Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

    2/2/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

    Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de

    11/12/25 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

    MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano MedAppointed Martin Steegmaier, Ph.D. as CSO and member of Executive CommitteeCash and cash equivalents and short-term time deposits total of CHF 114 million as of June 30, 2025, extending runway into 2028. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GL

    8/25/25 4:00:00 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $AKAN
    $BGXX
    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Portage Biotech Inc.

    SC 13G/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

    11/14/24 4:26:22 PM ET
    $PRTG
    Oil & Gas Production
    Energy

    Amendment: SEC Form SC 13D/A filed by Portage Biotech Inc.

    SC 13D/A - PORTAGE BIOTECH INC. (0001095435) (Subject)

    11/14/24 4:07:02 PM ET
    $PRTG
    Oil & Gas Production
    Energy